9 Companies Hiring in Oncology
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
New analysis from Jefferies shows that rare disease and cancer drugs granted the status are especially likely to be approved.
Nearly Three Quarters of FDA Breakthrough Designated Drugs Win Approval: Report Read More »
The insurer accused the health systems of putting business interests over patient well-being in recent failed contract negotiations.
UnitedHealthcare swipes at Johns Hopkins, Capital Women’s Care in contract brawl Read More »
En el mundo digital, hay un encanto especial en tener documentos físicos. Sin embargo, los apuntes, borradores y notas que se acumulan con el tiempo suelen terminar en carpetas desordenadas, volviéndose difíciles de consultar y fáciles de perder. La soluci&oacut …
Tus notas, tu libro: Técnicas básicas para encuadernar tus apuntes en casa Read More »
Adam Kautzner will oversee the PCMA’s strategy as chair of the board, including its defense of pharmacy benefit managers amid growing scrutiny of their role in rising drug costs.
Influential PBM lobby appoints top Express Scripts executive as board chair Read More »
Investment in 2025 has reached $9.9 billion, exceeding the $8.4 billion that was raised through the third quarter last year, according to Rock Health.
Digital health funding outpacing last year as huge rounds increase: report Read More »
The sale will leave Owens & Minor focused on a smaller but potentially faster-growing and higher-margin business that provides products directly to patients.
Owens & Minor inks $375M deal to sell unit to investment firm Read More »
Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.
The centerpiece of the deal is orelabrutinib, a BTK inhibitor in late-stage development for multiple sclerosis that Biogen once paid $125 million for but abandoned after less than two years of testing.
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare Read More »
Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.
Medtech M&A has remained slow this year. But 2 execs are ready to make a deal Read More »